Prostate Cancer News and Research

Latest Prostate Cancer News and Research

Do statins make radiation more effective at curing prostate cancer?

Patients with prostate cancer who receive high-dose radiation treatment and also take statin drugs commonly used to lower cholesterol have a 10 percent higher chance of being cured of their cancer at 10 years after diagnosis (76 percent), compared to those who don't take these medications (66 percent), according to a study presented at a scientific session October 31, 2007, at the American Society for Therapeutic Radiology and Oncology's 49th Annual Meeting in Los Angeles.

29 Oct 2007

Kaiser Daily Health Policy Report reports on Presidential campaigns related to health care

Forty-six percent of U.S. adults who responded to a recent survey conducted by Scripps Howard and Ohio University said that Democrats were more likely to improve access to health care than Republicans, Scripps Howard/Richmond Times-Dispatch reports. The survey, which included responses from 811 adults nationwide collected from Sept 24. to Oct. 10, has a margin of error of plus or minus four percentage points.

29 Oct 2007

Walking prevents bone loss caused from prostate cancer treatment

Exercise may reduce, and even reverse, bone loss caused by hormone and radiation therapies used in the treatment of localized prostate cancer, thereby decreasing the potential risk of bone fractures and improving quality of life for these men, according to a study presented on October 28, 2007, at the American Society for Therapeutic Radiology and Oncology's 49th Annual Meeting in Los Angeles.

28 Oct 2007

Highly targeted radiation therapy for prostate cancer prevents damage to surrounding organs

Oregon Health & Science University Cancer Institute researchers have found that highly targeted radiation therapy for prostate cancer can ensure that the majority of persons with this tumor will not have any long-term rectal damage.

28 Oct 2007

Emerging cancer therapies and novel targets

What are the cancer drugs of tomorrow and how will they be developed? At the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, researchers will present some answers to these and other pressing questions regarding emerging cancer therapeutics.

25 Oct 2007

Potential early warning system for lung cancer identified

The British Midlands Development Corporation announced that new research from The University of Nottingham has pinpointed a potential early warning system for lung cancer.

25 Oct 2007

Potent inhibitor of Kinesin CENP-E demonstrates tumor cell inhibition

A first-in-class, targeted investigational therapy specifically designed to inhibit a single protein that functions only during cell division shows potent activity in a broad range of cancer cell lines, say researchers from GlaxoSmithKline.

24 Oct 2007

Experimental cancer pharmaceuticals under trial

A potent and selective inhibitor of the mitotic kinesin CENP-E (GSK923295A) demonstrates a novel mechanism of inhibiting tumor cell proliferation and shows activity against a broad panel of human tumor cell lines in vitro: Abstract A 111.

24 Oct 2007

Health Discovery receives notice of allowance of U.S. patent application covering kernel selection methods

Health Discovery Corporation has announced that the U.S. Patent and Trademark Office has issued a notice of allowance of HDC's patent application covering methods for selection of kernels, i.e., functions or algorithms that are used to transform input data into a different configuration, known as "feature space", which allows for easier recognition of patterns within the data.

18 Oct 2007

Phase II map of human genetic variation

The International HapMap Consortium today published analyses of its second-generation map of human genetic variation, which contains three times more markers than the initial version unveiled in 2005.

18 Oct 2007

British 'Nurse of the Year' quits the NHS

Britain's star nurse has quit her job with the National Health Service (NHS) only eight months after being named 'Nurse of the Year'.

17 Oct 2007

$Prostate cancer increases likelihood of hip fracture four fold$

Prostate cancer increases likelihood of hip fracture four fold

Men who have prostate cancer are on average four times more likely to suffer a hip fracture, with rates rising to eight times in men aged 50 to 65, according to a study of more than 60,000 men published in the October issue of the urology journal BJU International.

12 Oct 2007

New research may show why some prostate cancer recurs after treatment

Cancer researchers have long worked to understand why some prostate cancers recur after the use of therapies designed to stop the production of testosterone and other androgens that fuel cancer cell growth.

12 Oct 2007

New molecules discovered that block cancer cells from modifying cell DNA

Researchers have discovered new small molecules that may prevent prostate cancer cells from turning off normal genes in a process that transforms normal cells into cancer cells. This significant discovery in the field of epigenetics has immediate implications in the development of new diagnostic tests and cancer medications.

12 Oct 2007

Immune system protein shows potential as early warning system for lung cancer

An immune system protein could act as an early warning system for lung cancer, reveals research published ahead of print in the journal Thorax.

10 Oct 2007

PSA velocity's value as a prostate cancer screening tool

Some studies have suggested that the rate of change of prostate-specific antigen (PSA) levels may correspond with prostate cancer survival.

10 Oct 2007

Androgen deprivation therapy linked to increased risk of heart disease death

The use of androgen deprivation therapy to treat localized prostate cancer is associated with an increased risk of death from heart disease, according to a study published online October 9 in the Journal of the National Cancer Institute .

10 Oct 2007

African-American men have a slightly higher risk of PSA recurrence

African-American men are more likely to have their prostate cancer return after treatment, but their disease is no more aggressive when it does recur than that of their white counterparts, according to a study led by Duke Prostate Center researchers.

10 Oct 2007

Intensity modulated radiation therapy better for sparing bladder when treating prostate cancer

When treating early-stage prostate cancer, intensity modulated radiation therapy (IMRT) spares the bladder significantly more from direct radiation when compared to 3-D conformal proton therapy (3D-CPT), but the amount of rectal sparing is similar with both treatments, according to a study released in the October issue of the International Journal for Radiation Oncology*Biology*Physics, the official journal of the American Society for Therapeutic Radiology and Oncology.

10 Oct 2007

Surgery may offer best chance of long-term prostate cancer survival

A study from Switzerland suggests that men who have surgery for prostate cancer appear less likely to die of the disease within 10 years than men who choose other treatment options, especially if they are younger or have cancers with certain tumor cell characteristics, according to a report in the Oct. 8 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

9 Oct 2007